Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trial

Rhythm Pharmaceuticals unveiled initial data from a mid-stage study of its MC4R agonist in patients with a rare disease that causes excessive hunger. The biotech’s Imcivree led to BMI reductions in six out of eight ...